All lobbying filings

TODD STRATEGY GROUP

TODD STRATEGY GROUP filed a Q3 report for ALNYLAM PHARMACEUTICALS, INC. on October 19, 2026, reporting $60,000 in lobbying income.

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Biopharmaceutical company

All filings by TODD STRATEGY GROUP · Everything ALNYLAM PHARMACEUTICALS, INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Lobbyists on this filing 4

PAUL EDATTEL

Previously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
KATHERINE FLEMING COTTON

Previously held: Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
ERIC BERGREN

Previously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
NICOLAS MAGALLANES

Previously held: Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Medicare/Medicaid

Issues related to the implementation of the Inflation Reduction Act. Home infusion policy. Issues related to MFN drug pricing.

Trade (domestic/foreign)

Issues relating to supply chain tariffs.

Pharmacy

Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94). Drug Pricing. FY2026 Labor HHS appropriations. Genetically targeted technologies. Policies related to medical innovation.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.